- Home
- AIFF vs RNXT Comparison
AIFF vs RNXT Comparison
Compare AIFF & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIFF
- RNXT
- Stock Information
- Founded
- AIFF 2006
- RNXT 2012
- Country
- AIFF Canada
- RNXT United States
- Employees
- AIFF N/A
- RNXT N/A
- Industry
- AIFF
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- AIFF
- RNXT Health Care
- Exchange
- AIFF NYSE
- RNXT Nasdaq
- Market Cap
- AIFF 26.6M
- RNXT 30.0M
- IPO Year
- AIFF N/A
- RNXT 2021
- Fundamental
- Price
- AIFF $2.33
- RNXT $1.25
- Analyst Decision
- AIFF
- RNXT Strong Buy
- Analyst Count
- AIFF 0
- RNXT 2
- Target Price
- AIFF N/A
- RNXT $6.50
- AVG Volume (30 Days)
- AIFF 59.4K
- RNXT 112.3K
- Earning Date
- AIFF 11-14-2024
- RNXT 11-13-2024
- Dividend Yield
- AIFF N/A
- RNXT N/A
- EPS Growth
- AIFF N/A
- RNXT N/A
- EPS
- AIFF N/A
- RNXT N/A
- Revenue
- AIFF $74,000.00
- RNXT N/A
- Revenue This Year
- AIFF N/A
- RNXT N/A
- Revenue Next Year
- AIFF N/A
- RNXT N/A
- P/E Ratio
- AIFF N/A
- RNXT N/A
- Revenue Growth
- AIFF N/A
- RNXT N/A
- 52 Week Low
- AIFF $2.32
- RNXT $0.77
- 52 Week High
- AIFF $15.90
- RNXT $2.35
- Technical
- Relative Strength Index (RSI)
- AIFF 32.31
- RNXT 51.48
- Support Level
- AIFF $2.89
- RNXT $1.10
- Resistance Level
- AIFF $3.25
- RNXT $1.31
- Average True Range (ATR)
- AIFF 0.28
- RNXT 0.14
- MACD
- AIFF -0.07
- RNXT -0.03
- Stochastic Oscillator
- AIFF 0.93
- RNXT 33.33
About AIFF FIREFLY NEUROSCIENCE INC
Firefly Neuroscience Inc is an AI company developing innovative neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support better outcomes for people suffering from mental illnesses and cognitive disorders.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.